Drug Type Small molecule drug |
Synonyms NIP 142, NIP-142, NIP142 |
Target |
Action inhibitors |
Mechanism EGFR exon 20 inhibitors(EGFR exon 20 Mutation inhibitors), HER2 exon 20 inhibitors(ERBB2 Exon 20 Mutation inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H27N3O6 |
InChIKeyHWADWMAQVCHLHJ-MMYMAHBISA-N |
CAS Registry203002-58-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | Phase 1 | China | 11 May 2022 | |
Non-Small Cell Lung Cancer | Phase 1 | China | 30 Jan 2022 |